Literature DB >> 8880982

IgG subclasses of canine anti-erythrocyte, antinuclear and anti-thyroglobulin autoantibodies.

M J Day1.   

Abstract

A panel of monoclonal antibodies (mAbs) reactive with the four canine IgG subclasses (IgG1, IgG2, IgG3 and IgG4) was used to investigate the activity of IgG subclasses in autoimmune responses to erythrocytes, nuclear antigens and thyroglobulin in dogs with autoimmune disease. mAbs specific for canine IgG1 and IgG4 were able to agglutinate normal dog erythrocytes coated with purified canine IgG containing each of the four subclasses. IgG1 autoantibodies were demonstrated on the surface of erythrocytes from seven dogs with Coombs'-positive autoimmune haemolytic anaemia and IgG4 autoantibodies were also present in two of these cases. Serum antinuclear antibody was shown in nine dogs to be predominantly of IgG1, IgG3 and IgG4 subclasses with only one of the dogs also producing an IgG2 antinuclear antibody. The IgG subclass profile of antinuclear antibodies differed between dogs with polyarthritis and dogs with other systemic disease. In six dogs with hypothyroidism, thyroglobulin autoantibodies of subclasses, IgG1, IgG2 and IgG4 predominated, but one dog also produced significant levels of IgG3 thyroglobulin autoantibodies. The mAbs are widely applicable to the study of the pathogenesis of canine autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880982     DOI: 10.1016/s0034-5288(96)90087-9

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  2 in total

Review 1.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

2.  Prevalence of antinuclear antibodies and rheumatoid factor titers in dogs with arthritis secondary to leishmaniosis (Leishmania infantum).

Authors:  Theodora K Tsouloufi; Konstantina Theodorou; Michael J Day; Ioannis L Oikonomidis; Dimitrios Kasabalis; Mathios E Mylonakis; Manolis N Saridomichelakis; Maria Kritsepi-Konstantinou; Nectarios Soubasis
Journal:  J Vet Diagn Invest       Date:  2022-06-02       Impact factor: 1.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.